

This page includes information pertaining to the capital increases announced by Clariane in relation to its refinancing plan.

Access to the information available in this page may be restricted in certain countries by applicable laws and regulations. Persons who are physically located in those jurisdictions and who would like to access the information available in this page must inform themselves about and observe such restrictions.

The information available in this page may be freely accessed by French residents who are physically located in France.

*With respect to each Member State of the European Economic Area other than France (the “**Relevant Member States**” and individually, a “**Relevant Member State**”) and the United Kingdom which are subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the “**Prospectus Regulation**”) as it also forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the “**EUWA**”), the information available in this page is directed only at any legal entity which is a qualified investor as defined in the Prospectus Regulation, as it also forms part of domestic law of the United Kingdom by virtue of the EUWA. These restrictions with respect to any Relevant Member State or the United Kingdom apply in addition to any other restrictions which may be applicable in any Relevant Member State or the United Kingdom.*

*This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “**United States**”), Japan, South Africa or Australia, and do not constitute, and shall not be construed as, an offer to sell or a solicitation of an offer to purchase or acquire, directly or indirectly, any shares or other securities of Clariane in the United States, Japan, South Africa or Australia or to, or for the account or benefit of, any person resident in the United States, Japan, South Africa, Australia including any corporation or other entity organized under the laws of the United States, Japan, South Africa or Australia. The shares or other securities of Clariane referred to in this page have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”), and may not be offered or sold in the United States absent registration under or pursuant to an exemption from, or in a transaction not subject to, the registration under the U.S. Securities Act. Clariane does not intend to register securities or conduct a public offering in the United States.*

All persons residing outside of France and outside of the United States, Japan, South Africa and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained. Clariane assumes no responsibility if there is a violation of applicable law and regulations by any person.

Any forward-looking statements in this page are based on Clariane’s current assumptions and expectations and, by their nature, forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Clariane’s control, that could cause actual business results and performance to differ materially from any expected future results or performance expressed or implied by any forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements. Neither Clariane, nor any of its directors, officers, employees, agents, affiliates or advisers accepts any responsibility whatsoever for the reasonableness of assumptions made or opinions stated or the likelihood of the achievement of projections, prospects or returns. Any responsibility or liability for any such information is expressly disclaimed. Nothing in this page is, or should be relied upon as, a promise or representation of the future. In addition, no statement in this page is intended to be nor may be construed as a profit forecast. Past performance of Clariane cannot be relied on as a guide to future performance.

By accessing to the information available in this page, you confirm that you are in compliance, and agree to comply, with the restrictions described above.